-
Canaccord Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
Barclays Downgrades Pacific Biosciences of California (PACB) to Underweight
-
Pacific Bio (PACB) Tops Q4 EPS by 3c
-
Canaccord Genuity Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
Canaccord Genuity Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
PacBio announces collaboration plans for rare disease therapies
-
PacBio reports fourth quarter revenue growth of 14% year-over-year
-
PacBio and UC Davis develop CiFi sequencing method for genome assembly
-
Pacific Bio (PACB) Tops Q3 EPS by 3c
-
PacBio partner gets China approval for clinical long-read sequencer
-
Canaccord Genuity Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
PACB announces cost reductions for genome sequencing platforms
-
PacBio technology chosen for South Korea's national genome project
-
PACB expands PureTarget portfolio for carrier screening market
-
PacBio partners with EpiCypher for chromatin sequencing workflow
-
Pacific Biosciences of California (PACB) PT Raised to $1.70 at Bernstein SocGen Group
-
Pacific Bio (PACB) Tops Q2 EPS by 4c
-
QIAGEN launches long read sequencing panels for complex genomic analysis
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
Pacific Bio (PACB) Board investigation sees allegations as unsubstantiated
-
Pacific Biosciences of California (PACB) PT Lowered to $3 at Jefferies
-
Pacific Bio (PACB) Tops Q1 EPS by 4c
-
Pacific Bio (PACB) to Improve Methylation Detection in HiFi Chemistry
-
Pacific Bio (PACB) partners with Davos Alzheimer's Collaborative
-
Canaccord Genuity Reiterates Buy Rating on Pacific Biosciences of California (PACB)
-
Pacific Bio (PACB) Reports Prelim Q1 Revenue, Affirms FY25 Guidance
-
Pacific Bio (PACB) Appoints Jim Gibson as CFO
-
Pacific Biosciences of California (PACB) PT Lowered to $2 at Scotiabank
-
Cantor Fitzgerald Reiterates Overweight Rating on Pacific Biosciences of California (PACB)
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Increasing unusual option volume: EGY FEZ CMRX PACB
-
Increasing unusual call option volume: GT XLI HLF ALGM FROG PACB ABSI
-
Pacific Bio (PACB) Reports In-Line Q4 EPS, Misses on Revenue
-
Pacific Bio (PACB) names David Ruggiero as new Global Head of Sales
-
Pacific Bio (PACB) Appoints Chris Smith to its Board
-
Pacific Bio (PACB) Announces Preliminary Fourth Quarter and Full Year Revenue
-
Pacific Bio (PACB) Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Pacific Bio (PACB) Tops Q3 EPS by 5c
-
Pacific Bio (PACB) Announces SPRQ Chemistry for Revio Sequencing Systems
-
Pacific Bio (PACB) Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
-
Pacific Biosciences of California (PACB) PT Lowered to $7 at Scotiabank
-
Form Bio and PacBio Announce Collaboration to Launch New Resources Set to Transform AAV Design and Analysis Best Practices
-
Pacific Bio (PACB) and International Research Consortium CoLoRS Announce Release of First-Ever HiFi Long-Read Variant Database

